MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic (Q39101546)
Jump to navigation
Jump to search
scientific article published on November 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic |
scientific article published on November 2013 |
Statements
1 reference
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinic (English)
1 reference
Juan J Gu
1 reference
Francisco J Hernandez-Ilizaliturri
1 reference
Cory Mavis
1 reference
Natalie M Czuczman
1 reference
George Deeb
1 reference
John Gibbs
1 reference
Joseph J Skitzki
1 reference
Ritesh Patil
1 reference
Myron S Czuczman
1 reference
1 November 2013
1 reference
1 reference
24
1 reference
10
1 reference
1030-1038
1 reference
1 reference
Identifiers
1 reference
1 reference